Study on Local Irritation in Rabbits and Micronucleus Test in Mice with YHB216

YHB216의 토끼에서 국소독성시험 및 마우스에서 소핵시험

  • 강민정 ((주)유한양행 중앙연구소) ;
  • 김미영 ((주)유한양행 중앙연구소) ;
  • 박명규 ((주)유한양행 중앙연구소) ;
  • 김봉태 ((주)유한양행 중앙연구소) ;
  • 안경규 ((주)유한양행 중앙연구소) ;
  • 최연식 ((주)유한양행 중앙연구소) ;
  • 문병석 ((주)유한양행 중앙연구소) ;
  • 이종욱 ((주)유한양행 중앙연구소)
  • Published : 2002.03.01


YHB216 is one of new recombinant human erythropoietins (rHu-EPO) developed by Yuhan Research Institute. The rHu-EPO products are widely being used for the treatment of various types of anemia. As a series of safety studies on YHB216, we performed the local irritation test (dermal & ocular application) in male New Zealand White rabbits and micronucleus test in male ICR mice. In the skin irritation test, 0.5 ml of YHB216 10,000 IU/ml solution was applied to the back skin of rabbits for 24 hours and sub-sequent observation was performed. There was no induced response after the treatment and the primary irritation index (P.I.I.) was‘0’. In the eye irritation test, 0.1 ml of YHB216 10,000 IU/mL solution was instilled into the conjunctiva of the eye. No treatment-related reaction was observed at the cornea, iris, and conjunctiva. In the micronucleus test, YHB216 was administered intravenously to male mice (6 mice per group) at dose levels of 0, 6,250, 12,500, and 25,000 IU/kg. Bone marrow cells were collected at 24 hours after the treatment. YHB216 treated groups showed no significant difference in the P/N (polychromatic erythrocyte/ normochromatic erythrocyte) ratio and in the number of micronucleated polychromatic erythrocyte com-pared with the control. In conclusion, YHB216 was found to be a non-irritating material up to 10,000 IU/ml in the local irritation test and to be a non-mutagen up to 25,000 IU/kg in the micronucleus test.



  1. Ophthalmic toxicology in General & Applied Toxicology Ballantyne B.;Ballantyne B.(ed.)
  2. rabbits;J. Toxicol. Pub. Health v.14 Studies on local irritation of DA-3585;a recombinant human erythropoietin Cho H.;Kim D.H.;Kang K.K.;Park J.H.;Lee S.H.;Kim W.B.
  3. J. Pharmacol. Exp. Ther. v.82 Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes Draize J.H.;Woodward G.;Calvery H.O.
  4. Am. J. Kidney Dis. v.14 Guidelines for recombinant human erythropoietin therapy Eschbach J.W.;Adamson J.W.
  5. Progress in Drug Research v.41 Recent advances in erythropoietin research Fisher J.W.;Ernst Jucker(eds.);
  6. distribution and evaluation of results;Mutation Research v.111 Statistics of mouse bone-marrow miconucleus test: counting Hart J.W.;Engberg-Pedersen H.
  7. Environ Health perspect. v.102 Statistical analysis of data in mutagenicity assays; rodent micronucleus assay Hayashi M.(et al.)
  8. 臨床醫藥 v.6 Mutagenicity test on EPOCH Inoue M.;Horiuchi K.;Fukuda T.;Fukuda A.;Yano M.;Matsuoka Y.;Koizumi T.;Kojima Y.;Satoh T.
  9. Nature v.179 Role of the kidney in erythropoiesis Jacobson L.O.;Goldwasser E.;Fied W.;Plzak L.
  10. The Clinical Report? v.22 Primary eye irritation study of KRN5702 in rabbits Kawasaki H.(et al.)
  11. Environmental mutagens & Carcinogens v.16 Genotoxic evaluation of recombinant human erythropoietin (rHu-EPO) in short-term assays Kim H.S.;Kwack S.J.;Chun S.A.;Lim S.Y.;Ahn M.Y.;Kim W.B.;Kim B.M.;Ahn B.O.;Suh D.S.;Lee B.M.
  12. Blood v.71 Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization Koury S.T.;Bondurant M.C.;Koury M.J.
  13. Proc. Natil. Acad. Sci. v.49 Cloning and expression of human erythropoietin gene Lin F.K.;Suggs S.;Lin C.H.;Browne J.K.;Smalling R.;Egrie J.C.;Cjen K.K.;Fox G.M.;Martin F.;Stabinsky Z.;Bdrawi S.;Lin P.H.;Goldwasser E.
  14. Fundam. Appl. Toxicol. v.14 The in vivo erythrocyte micronucleus test: measurement at steady state increases assay efficiency and permits integration with toxicity studies MacGregor J.T.(et al.)
  15. Brit. J. Hematol. v.74 Erythropoietin production in kidney tubular cells Maxwell A.P.;Lappin T.R.J.;Johnston C.F.;Bridges J.M.;McGeown M.G.
  16. 藥理と治療 v.18 General pharmacological studies of erythropoietin (TYB-5220) Mino T.;Ohmura T.;Hiraoka Y.;Sugino T.;Hayashi H.
  17. 藥理と治療 v.18 Metabolic fate of erythropoietin (TYB-5220) Okumura K.;Aoki S.;Sugino T.;Ono T.;Nagano N.;Iba Y.
  18. Dermatotoxicology in Principles and Methods of Toxicology Patrick E.;Maibach H.;Hayes A.W.(ed.)
  19. J. Natl. Med. Assoc. v.86 Erythropoietin : A riew Ridley D.M.;Dawkins F.;Perlin E.
  20. The Clinical Report? v.22 Mutagenicity study of KRN5702 Sutou S.(et al.)
  21. Mutagenesis v.4 The micronucleus test and erythropoiesis;Effects of erythropoietin and a mutagen on the ratio of polychromatic to normochromatic erythrocytes (P/N ratio) Suzuki Y.;Nagae Y.;Li J.;Sakaba H.;Mozawa K.;Takahashi A.;Shimizu H.
  22. Netherlands J. Med. v.42 Erythropoietin; mechanisims of action and indication for treatment Vreundenhil G.;Frenken L.A.M.;Koene R.A.P.
  23. 식품의약품안전청 고시 제 1999-61호 의약품 등의 독성시험기준 식품의약품안전청
  24. 식품의약품안전청 고시 제 2000-63호 비임상시험관리기준 식품의약품안전청